
RayzeBio Investor Relations Material
Latest events

Q3 2023
13 Nov, 2023

Corporate Presentation
12 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RayzeBio Inc
Access all reports
RayzeBio Inc is a biotechnology firm concentrated on developing radiopharmaceutical therapeutics (RPT) for cancer treatment. Their leading drug candidate, RYZ101, is in clinical trials aimed at treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Additionally, RayzeBio is working on RYZ801, a novel proprietary peptide targeting GPC3 for the treatment of hepatocellular carcinoma (HCC), among other innovative drug candidates targeting various cancers. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
RYZB
Country
🇺🇸 United States